Analyst Raises Eli Lilly's Price Target Following Strong Q1 Results

Guggenheim analyst Seamus Fernandez raised Eli Lilly’s (LLY) price target to $1,235 from $1,183 following the company’s strong first-quarter results. The firm maintained a 'Buy' rating as LLY reported significant revenue and earnings growth driven by demand for its GLP-1 drugs.

By Sultan Khalid Fri, May 15, 2026 at 11:45 AM GMT+3 2 min read · Yahoo Finance · May 15, 2026, 08:45 UTC

Analyst Raises Eli Lilly's Price Target Following Strong Q1 Results

Tickers: $LLY

Topics: Eli Lilly GLP-1 Drugs Pharmaceuticals Q1 Results

Read the full article at Yahoo Finance

More World news

Fennec Pharmaceuticals Reports Record Q3 2026 Results with Significant EBITDA Growth Motley Fool · November 12, 2026, 16:11 UTC
Rockwell Medical Reports Q3 2026 Results and Announces Vantive Limited Acquisition Motley Fool · November 12, 2026, 16:11 UTC
BioHarvest Sciences Reports Q3 2026 Financial Results Amid Strategic Shift to Fragrance Development Motley Fool · November 12, 2026, 16:11 UTC
Xunlei Reports Q3 2026 Revenue Growth Amid Increased Operating Losses and Investment Adjustments Motley Fool · November 12, 2026, 16:11 UTC
Sandisk Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 16:14 UTC
Donald Trump Suggests Tim Cook as Potential Successor for Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 16:09 UTC
Yankees President Randy Levine Advocates for Protect College Sports Act and Addresses MLB Labor Uncertainty CNBC · November 12, 2026, 15:34 UTC
Donald Trump Suggests Apple Chairman Tim Cook as Potential Successor to Nvidia CEO Jensen Huang TechCrunch · November 12, 2026, 16:12 UTC
Bybit Announces Title Partnership for Inaugural Stockholm Open ATP 250 Tournament PR Newswire · November 12, 2026, 16:11 UTC
SES AI Reports Q3 2026 Revenue Growth Amid Strategic Shift Toward Drone Battery Market Motley Fool · November 12, 2026, 16:10 UTC